Status:

UNKNOWN

DHA Supplements to Improve Insulin Sensitivity in Obese Pregnant Women (The Omega-3 Pregnancy Study)

Lead Sponsor:

National Heart, Lung, and Blood Institute (NHLBI)

Collaborating Sponsors:

Office of Research on Women's Health (ORWH)

Mead Johnson Nutrition

Conditions:

Overweight and Obesity

Insulin Resistance

Eligibility:

FEMALE

18-40 years

Phase:

PHASE1

Brief Summary

Women with excess adiposity while pregnant are more likely to develop gestational diabetes and high blood pressure during pregnancy than women of healthy weights. This may occur because overweight and...

Detailed Description

The effects of overweight and obesity during pregnancy on maternal and child health can be serious and long lasting. Overweight and obese women are more likely to develop gestational diabetes or pre-e...

Eligibility Criteria

Inclusion

  • Pre-pregnant body mass index greater than 25
  • Singleton pregnancy
  • Speaks English

Exclusion

  • High intake of DHA foods (i.e., more than 1 fish meal per week, use of DHA-fortified foods, or use of any supplements that contain DHA)
  • Concurrent inflammatory, vascular, or metabolic disease, including diabetes, polycystic ovary disease, collagen vascular disease, inflammatory bowel disease, or infection
  • Current or previous use of tobacco, street drugs, or medications known to affect inflammatory markers, including corticosteroids
  • Excessive weight gain or loss before pregnancy (more than 20 pounds), including weight loss due to bariatric surgery
  • Plans to leave the area during the study period
  • Inability to travel to General Clinical Research Center

Key Trial Info

Start Date :

April 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2011

Estimated Enrollment :

90 Patients enrolled

Trial Details

Trial ID

NCT00865683

Start Date

April 1 2009

End Date

July 1 2011

Last Update

July 15 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

General Clinical Research Center

Cincinnati, Ohio, United States, 45229-3039